Program
Immunoglobulin G
Also written as “HYQVIA”, “HyQvia” and “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”.
Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Prostatic Neoplasms · Autoimmune Diseases of the Nervous System · Alzheimer Disease, led by 6 companies.
Drug pageImmunoglobulin G: every studyMany companies study it; this page follows only the 13 they lead. All 241 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 60 open or running | phase 4since Apr 12, 2017 | Sep 11, 2015 | none ahead |
| GC Biopharmaits history only | 30 open or running | phase 4since Jan 25, 2012 | Mar 14, 2011 | none ahead |
| CSLits history only | 10 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Genmabits history only | 10 open or running | phase 2since May 14, 2020 | May 14, 2020 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 1since May 30, 2025 | May 30, 2025 | none ahead |
| Proclara Biosciences | 10 open or running | phase 1since Dec 23, 2016 | Dec 23, 2016 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, AbbVie and Symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Proclara Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2016First study: phase 1 study in Alzheimer DiseaseFirst studyNCT03008161 · 83 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Proclara Biosciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03008161Alzheimer Disease · United States | 1 | Completed | Feb 6, 2019 | 83 |
How it is read
Names in the registry
- “HYQVIA”, 10 entries
- “Immunoglobulin G”, 3 entries
- “HyQvia”, 1 entry
- “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”, 1 entry
- “NPT088”, 1 entry
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Prostatic Neoplasms, 1 study
- Autoimmune Diseases of the Nervous System, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.